Edition:
India

Minerva Neurosciences Inc (NERV.OQ)

NERV.OQ on NASDAQ Stock Exchange Global Market

8.10USD
1:30am IST
Change (% chg)

$-0.05 (-0.61%)
Prev Close
$8.15
Open
$8.10
Day's High
$8.15
Day's Low
$7.95
Volume
14,258
Avg. Vol
38,389
52-wk High
$9.25
52-wk Low
$4.90

Chart for

About

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company's product portfolio and indications include MIN-101 for the treatment... (more)

Overall

Beta: --
Market Cap(Mil.): $320.94
Shares Outstanding(Mil.): 42.51
Dividend: --
Yield (%): --

Financials

BRIEF-Minerva Neurosciences Q1 Loss Per Share $0.32

* MINERVA NEUROSCIENCES REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND BUSINESS UPDATES

03 May 2018

BRIEF-Minerva Neurosciences Reports Q1 Loss Per Share $0.32

* MINERVA NEUROSCIENCES REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND BUSINESS UPDATES

03 May 2018

BRIEF-Minerva Neurosciences Screens First Patient In Phase 2B Trial Of Min 117 To Treat Major Depressive Disorder

* MINERVA NEUROSCIENCES SCREENS FIRST PATIENT IN PHASE 2B TRIAL OF MIN 117 TO TREAT MAJOR DEPRESSIVE DISORDER

09 Apr 2018

BRIEF-Minerva Neurosciences Reports Fiscal 2017 Fourth Quarter And Year End Financial Results

* MINERVA NEUROSCIENCES REPORTS FISCAL 2017 FOURTH QUARTER AND YEAR END FINANCIAL RESULTS AND BUSINESS UPDATES

12 Mar 2018

BRIEF-Minerva Neurosciences Names Remy Luthringer As Executive Chairman

* MINERVA NEUROSCIENCES NAMES REMY LUTHRINGER AS EXECUTIVE CHAIRMAN AND WILLIAM DOYLE AS LEAD INDEPENDENT DIRECTOR

05 Feb 2018

BRIEF-Minerva Neurosciences Names Remy Luthringer As Executive Chairman

* MINERVA NEUROSCIENCES NAMES REMY LUTHRINGER AS EXECUTIVE CHAIRMAN AND WILLIAM DOYLE AS LEAD INDEPENDENT DIRECTOR

05 Feb 2018

Competitors

Earnings vs. Estimates